NewsBenzingaTaseko Mines 3. Çeyrek Düzeltilmiş Hisse Başına Kârı (EPS) 0,11 Dolar, Beklentilere Paralel, Satışlar 244,552 Milyon Dolar ile Geçen Yılın Aynı Dönemindeki 124,273 Milyon Dolardan Yükseldi Taseko Mines 3. Çeyrek Düzeltilmiş Hisse Başına Kârı (EPS) 0,11 Dolar, Beklentilere Paralel, Satışlar 244,552 Milyon Dolar ile Geçen Yılın Aynı Dönemindeki 124,273 Milyon Dolardan Yükseldi Benzinga 2026.11.04 23:20 (GMT+0) Open on Benzinga Other news ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate Bithumb to Delist Fetch.ai (FET) on December 7 Sony Group Q2 EPS ¥76.48, Sales ¥3.429T
ConocoPhillips Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Reported Earlier, Comstock Resources Q3 Adj. EPS $0.02 Misses $0.04 Estimate, Sales $384.363M Miss $424.364M Estimate
Reported Earlier, HUTCHMED’s Oral Syk Inhibitor Sovleplenib Gets US FDA Orphan Drug Designation For Autoimmune Hemolytic Anemia, Its Second After Primary ITP, Eligible For 7 Years Of US Market Exclusivity Upon Approval
Reported Earlier, Gold Royalty Q3 Adj. EPS $0.02 Beats $0.01 Estimate, Sales $10.246M Beat $8.235M Estimate
